Jpmorgan Chase & CO Humanigen, Inc Put Options Transaction History

Jpmorgan Chase & CO

  • $1.22 Trillion
  • Q3 2024

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email